Related Experiment Videos
Bisphosphonate therapy for severe osteogenesis imperfecta
1Department of Surgery, McGill University and Shriners Hospital, Montreal, Quebec, Canada. glorieux@shriners.mcgill.ca
Insights
Pamidronate treatment significantly improves bone mineral density and reduces fractures in children with severe Osteogenesis Imperfecta (OI). This therapy enhances mobility and pain relief without affecting growth or healing.
Area of Science:
- Pediatric Endocrinology
- Bone Metabolism
- Genetic Connective Tissue Disorders
Background:
- Osteogenesis Imperfecta (OI) is a group of genetic disorders primarily affecting type I collagen.
- Severe OI in children leads to recurrent fractures, deformities, and mobility issues.
Purpose of the Study:
- To evaluate the efficacy of cyclical intravenous pamidronate in managing severe Osteogenesis Imperfecta in children.
- To assess the impact of pamidronate on bone mineral density, fracture incidence, and clinical outcomes.
Main Methods:
- Cyclical intravenous administration of pamidronate was given to children with severe OI.
- Evaluated changes in bone mineral density, fracture rates, growth, pain, and fatigue.
Main Results:
- Pamidronate increased bone mineral density and decreased fracture incidence.
- Reduced dependence on mobility aids, with significant relief from chronic pain and fatigue.
- No adverse effects on fracture healing, growth rate, or growth plates were observed.
Conclusions:
- Pamidronate is the first therapy to significantly alter the natural course of severe OI.
- It improves clinical status and quality of life in affected children.
- While not addressing the underlying collagen defect, it offers substantial therapeutic benefits.
Abstract:
Osteogenesis imperfecta (OI) is a heterogeneous group of disorders principally affecting type I collagen. Children with the severe forms of the condition suffer recurrent fractures resulting in limb and spine deformities, and restricted ambulation. Recently, cyclical intravenous administration of pamidronate has proven of benefit to children with the severe forms of OI. Bone mineral density increased, and the incidence of fractures decreased. The treatment does not alter fracture healing, growth rate, or growth plate appearances. Dependence on mobility aids is reduced and there is substantial relief of chronic pain and fatigue. No significant adverse side effects have been noted. New bisphosphonates are under investigation to compare their effects to those of pamidronate. Although the use of bisphosphonates does not address the basic abnormalities that underlie the OI syndromes, it represents the first therapy to significantly alter the natural course of the disease and improve patients' clinical status and quality of life.